Exclusive: Cigna settles FTC insulin case, commits to overhauling drug pricing

Core Viewpoint - Cigna Corp's Express Scripts has reached a settlement with the U.S. Federal Trade Commission regarding claims that its insulin pricing practices violated antitrust and consumer protection laws, and has agreed to implement changes aimed at lowering insulin costs for consumers [1] Group 1: Settlement Details - The settlement addresses allegations of antitrust violations related to insulin pricing practices [1] - Changes agreed upon by Express Scripts are intended to reduce insulin costs for consumers [1] Group 2: Regulatory Context - The U.S. Federal Trade Commission's involvement highlights ongoing scrutiny of pharmaceutical pricing practices [1] - This settlement may set a precedent for future regulatory actions against similar pricing practices in the healthcare industry [1]